WordPress database error: [Table 'crumcg5_wpcru.nn_ctf_feeds' doesn't exist]
SELECT COUNT(*) FROM nn_ctf_feeds

WordPress database error: [Table 'crumcg5_wpcru.nn_ctf_feeds' doesn't exist]
SELECT COUNT(*) FROM nn_ctf_feeds

{"id":7708,"date":"2022-11-09T16:23:06","date_gmt":"2022-11-09T21:23:06","guid":{"rendered":"https:\/\/cru.mcgill.ca\/?p=7708"},"modified":"2023-06-03T08:11:08","modified_gmt":"2023-06-03T13:11:08","slug":"2022-retrospective","status":"publish","type":"post","link":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/","title":{"rendered":"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.9.10″ _module_preset=”default” background_enable_color=”off” width=”100%” max_width=”100%” min_height=”100px” height=”100px” max_height=”100px” custom_margin=”||||false|false” custom_padding=”100px||||false|false” global_module=”4368″ saved_tabs=”all” width__hover_enabled=”on|desktop”][et_pb_fullwidth_menu menu_id=”25″ menu_style=”centered” submenu_direction=”downwards” fullwidth_menu=”off” dropdown_menu_bg_color=”#353535″ dropdown_menu_line_color=”rgba(0,0,0,0)” dropdown_menu_text_color=”#ffffff” mobile_menu_bg_color=”rgba(0,0,0,0.67)” _builder_version=”4.8.1″ menu_font=”Fabriga||||||||” menu_text_color=”#ffffff” menu_font_size=”15px” menu_line_height=”0em” background_color=”#1e1e1e” background_size=”initial” background_position=”top_left” background_repeat=”repeat” background_layout=”dark” width=”100%” height=”52px” custom_margin=”-12px||0px||false|false” custom_margin_last_edited=”off|desktop” custom_padding=”0px||3px||false|false”][\/et_pb_fullwidth_menu][\/et_pb_section][et_pb_section fb_built=”1″ fullwidth=”on” admin_label=”Section” _builder_version=”4.9.10″ module_alignment=”center” custom_margin=”-80px||||false|false” custom_padding=”0px|0px|0|0px|false|false” box_shadow_style=”preset1″ box_shadow_vertical=”6px” box_shadow_blur=”37px” box_shadow_spread=”8px” global_module=”3032″ saved_tabs=”all”][et_pb_fullwidth_menu menu_id=”25″ menu_style=”centered” fullwidth_menu=”off” dropdown_menu_bg_color=”#353535″ dropdown_menu_line_color=”rgba(0,0,0,0)” dropdown_menu_text_color=”#ffffff” mobile_menu_bg_color=”rgba(0,0,0,0.67)” _builder_version=”4.9.10″ menu_font=”Fabriga||||||||” menu_text_color=”#ffffff” menu_font_size=”15px” menu_line_height=”0em” background_color=”#1e1e1e” background_size=”initial” background_position=”top_left” background_repeat=”repeat” background_layout=”dark” width=”100%” module_alignment=”left” height=”52px” custom_margin=”-12px||||false|false” custom_margin_last_edited=”off|desktop” custom_padding=”0px||0px||false|false”][\/et_pb_fullwidth_menu][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Hero” _builder_version=”4.9.10″ custom_margin=”|||0px|false|false” custom_padding=”0|0px|0|0px|false|false” bottom_divider_height=”0px” border_width_bottom=”1px” border_color_bottom=”#efefef”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”4.9.10″ width=”100%” max_width=”254%” min_height=”1084px” custom_margin=”|20px||0px|false|false” custom_margin_tablet=”||0px|” custom_margin_phone=”” custom_margin_last_edited=”on|desktop” custom_padding=”0px|50px||200px|false|false” hover_enabled=”0″ use_custom_width=”on” width_unit=”off” custom_width_percent=”100%” sticky_enabled=”0″][et_pb_column type=”3_5″ _builder_version=”4.3.4″ custom_padding=”||6%|12%|false|false” custom_padding_tablet=”|50px|50px|50px|false|false” custom_padding_phone=”” custom_padding_last_edited=”on|tablet” padding_tablet=”50px|50px|50px|50px” padding_last_edited=”on|tablet” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.10″ custom_margin=”40px||-10px||false|false” custom_padding=”0px||0px|||”]<\/p>\n

R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares<\/h1>\n

[\/et_pb_text][et_pb_image src=”https:\/\/cru.mcgill.ca\/wp-content\/uploads\/CRU-web-images-1.jpg” title_text=”CRU web images” align=”center” _builder_version=”4.9.10″ _module_preset=”default” custom_padding=”20px||||false|false”][\/et_pb_image][et_pb_text _builder_version=”4.9.10″ text_font=”Arial||||||||” custom_margin=”||||false|false” custom_padding=”0px||0px|||”]<\/p>\n

9 janvier 2023
<\/em>par Sophie Lorenzo<\/em><\/p>\n

L\u2019Unit\u00e9 de recherche clinique (URC) du Neuro vise \u00e0 rendre traitables toutes les maladies neurologiques et rares, en particulier celles pour lesquelles aucune option de traitement n\u2019est disponible. L\u2019ann\u00e9e 2022 a vu des progr\u00e8s significatifs dans l\u2019unit\u00e9 qui a entam\u00e9 des essais pour de nouveaux sous-types de maladies et qui s\u2019est jointe \u00e0 des efforts internationaux pour mieux comprendre des conditions complexes. Retour sur quelques moments forts.<\/p>\n

 <\/p>\n

ENTRA\u00ceNEMENT C\u00c9R\u00c9BRAL<\/strong><\/h3>\n

\u00c0 mesure que nous vieillissons, certains neurotransmetteurs (substances chimiques utilis\u00e9es par les neurones pour communiquer) qui sont importants pour l\u2019attention et la plasticit\u00e9 c\u00e9r\u00e9brale (la capacit\u00e9 du cerveau \u00e0 changer) ont tendance \u00e0 diminuer naturellement. Ce processus est acc\u00e9l\u00e9r\u00e9 dans certaines maladies neurod\u00e9g\u00e9n\u00e9ratives, comme la maladie d\u2019Alzheimer. Une \u00e9tude \u00e0 l\u2019URC examine l\u2019impact sur la sant\u00e9 neurologique d\u2019un programme d\u2019entra\u00eenement c\u00e9r\u00e9bral informatis\u00e9 ciblant un entra\u00eenement de l\u2019agilit\u00e9 et de la vivacit\u00e9 mentale. Gr\u00e2ce \u00e0 de nouvelles techniques d\u2019imagerie c\u00e9r\u00e9brale l\u2019\u00e9tude \u00e9valuera le niveau d\u2019ac\u00e9tylcholine des participants, un neurotransmetteur produit lorsque nous nous concentrons, en plus des r\u00e9sultats sur les mesures cognitives standards.\u00a0<\/span>En savoir plus<\/a>.<\/p>\n

 <\/p>\n

PROPULS\u00c9 PAR LA SCIENCE OUVERTE<\/strong><\/h3>\n

SLA<\/strong>\u00a0<\/span>: La scl\u00e9rose lat\u00e9rale amyotrophique se pr\u00e9sente et progresse diff\u00e9remment chez chaque patient, ce qui rend extr\u00eamement difficile le d\u00e9veloppement de th\u00e9rapies universelles pour cette maladie d\u00e9vastatrice. Or, des chercheurs canadiens esp\u00e8rent mieux comprendre cette variabilit\u00e9 gr\u00e2ce \u00e0 une nouvelle plateforme de recherche lanc\u00e9e cette ann\u00e9e. CAPTURE SLA vise \u00e0 accro\u00eetre la collaboration entre les scientifiques et impliquer les patients tout en d\u00e9veloppant l\u2019image la plus d\u00e9taill\u00e9e et la plus compl\u00e8te au monde de la maladie. Le Neuro joue un r\u00f4le central par le biais de son r\u00e9f\u00e9rentiel C-BIG, une biobanque en libre acc\u00e8s, qui h\u00e9bergera et partagera les donn\u00e9es et les \u00e9chantillons recueillis aupr\u00e8s de participants anonymis\u00e9s \u00e0 travers le Canada.\u00a0<\/span>En savoir plus<\/a>.<\/p>\n

Variantes g\u00e9n\u00e9tiques :<\/strong>\u00a0<\/span>La responsable des programmes nationaux pour la SLA g\u00e9n\u00e9tique \u00e0 l\u2019URC et des collaborateurs au Neuro indiquent comment la science ouverte peut aider \u00e0 identifier les patients qui risqueraient autrement d\u2019\u00eatre laiss\u00e9s dans l\u2019ignorance quant \u00e0 leur statut g\u00e9n\u00e9tique et leurs options de traitement. En analysant des \u00e9chantillons de patients atteints de SLA collect\u00e9s par la biobanque C-BIG du Neuro avant que le nouveau d\u00e9pistage g\u00e9n\u00e9tique pour le g\u00e8ne ATXN2 ne devienne disponible en 2020, l\u2019\u00e9quipe a pu identifier quatre personnes atteintes de variantes de ce g\u00e8ne qui ignoraient leur statut. Au fur et \u00e0 mesure que de nouvelles variantes g\u00e9n\u00e9tiques de la SLA seront identifi\u00e9es, les patients deviendront \u00e9ligibles pour de nouveaux essais cliniques adapt\u00e9s pour leur variante de la maladie.\u00a0<\/span>En savoir plus<\/a>.<\/p>\n

Maladie de Parkinson<\/strong>\u00a0<\/span>: Financ\u00e9e par la Fondation Michael J. Fox, l\u2019\u00e9tude r\u00e9volutionnaire Parkinson\u2019s Progression Markers Initiative (PPMI) analyse les marqueurs biologiques et la pr\u00e9sentation clinique de la maladie pour suivre les changements au fil du temps. En apprenant tout ce que nous pouvons sur la fa\u00e7on dont elle se d\u00e9veloppe, nous pouvons cr\u00e9er de meilleures th\u00e9rapies cibl\u00e9es et les tester avec plus de pr\u00e9cision dans des essais cliniques. Cette \u00e9tude suit les patients de mani\u00e8re exhaustive depuis le stade le plus pr\u00e9coce (prodromique) de la maladie \u2014 avant m\u00eame qu\u2019ils ne se pr\u00e9sentent dans un cabinet m\u00e9dical avec des tremblements ou une rigidit\u00e9 \u2014 au moment o\u00f9 ils peuvent d\u00e9velopper des troubles de l\u2019humeur, une perte d\u2019odorat et un trouble du comportement en sommeil paradoxal, qui ont tous une forte corr\u00e9lation avec le d\u00e9veloppement de la maladie. L\u2019un des objectifs de l\u2019\u00e9tude est de d\u00e9velopper des th\u00e9rapies neuro-protectrices capables d\u2019arr\u00eater ou pr\u00e9venir la maladie.\u00a0<\/span>En savoir plus<\/a>.<\/p>\n

 <\/p>\n

VICTOIRES POUR LES MALADIES RARES<\/strong><\/h3>\n

Myasth\u00e9nie grave<\/strong>\u00a0<\/span>: Jusqu\u2019en 2017, il n\u2019y avait eu aucun nouveau m\u00e9dicament pour la myasth\u00e9nie grave (MG) depuis pr\u00e8s de 60 ans. Certaines personnes atteintes de la MG ne r\u00e9pondent pas bien aux traitements disponibles, qui impliquent g\u00e9n\u00e9ralement la suppression \u00e0 long terme du syst\u00e8me immunitaire. L\u2019URC a \u00e9t\u00e9 impliqu\u00e9 dans l\u2019\u00e9tude de traitements ciblant des aspects sp\u00e9cifiques de la r\u00e9ponse immunitaire. Au cours des deux derni\u00e8res ann\u00e9es, un certain nombre de nouvelles th\u00e9rapies ont \u00e9t\u00e9 approuv\u00e9es qui sont beaucoup plus pr\u00e9cises dans leur traitement de la MG.\u00a0<\/span>En savoir plus<\/a>.<\/p>\n

 <\/p>\n

PREMI\u00c8RES \u00c0 L\u2019URC<\/strong><\/h3>\n

Tremblement essentiel :<\/strong>\u00a0<\/span>Le trouble du mouvement le plus courant est celui dont vous n\u2019avez probablement jamais entendu parler. Le tremblement essentiel (ET) provoque un tremblement rythmique involontaire qui est d\u00e9clench\u00e9 par le mouvement et affecte g\u00e9n\u00e9ralement les mains. C\u2019est une maladie \u00e0 progression lente, qui s\u2019aggrave avec le temps. Elle est huit fois plus r\u00e9pandue que la maladie de Parkinson, mais moins de 60 % des patients sont aid\u00e9s par les m\u00e9dicaments disponibles. Des essais sur des nouveaux traitements potentiels sont en cours \u00e0 l\u2019URC pour la premi\u00e8re fois dans notre centre.\u00a0<\/span>En savoir plus<\/a>.<\/p>\n

Charcot-Marie-Tooth :<\/strong>\u00a0<\/span>Bien qu\u2019elle soit plus r\u00e9pandue au Canada que la fibrose kystique ou la myasth\u00e9nie grave, la maladie de Charcot-Marie-Tooth (CMT) demeure moins connue. Or, 60% \u00e0 70% des individus atteints de cette neuropathie p\u00e9riph\u00e9rique h\u00e9r\u00e9ditaire ont une duplication de l\u2019ADN affectant un g\u00e8ne appel\u00e9 PMP22, qui \u00e0 son tour conduit \u00e0 la formation d\u2019une trop grande quantit\u00e9 d\u2019ARN, que l\u2019on pense \u00eatre toxique. Un nouvel essai \u00e0 l\u2019URC \u00e9tudiera comment une combinaison de trois m\u00e9dicaments courants pourrait potentiellement ralentir la progression de cette maladie rare. Le but des m\u00e9dicaments test\u00e9s est de voir s\u2019ils peuvent r\u00e9duire la quantit\u00e9 de cet ARN toxique.\u00a0<\/span>En savoir plus<\/a>.<\/p>\n

\u00a0<\/strong><\/p>\n

Pour tous les essais en cours \u00e0 l\u2019URC, contactez info-cru.neuro@mcgill.ca.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”4.3.4″ custom_padding=”|50px||50px|false|false” custom_padding__hover=”|||”][et_pb_social_media_follow icon_color=”#FFFFFF” use_icon_font_size=”on” icon_font_size=”18px” disabled_on=”on|on|on” admin_label=”Social Media Follow” _builder_version=”4.9.10″ _module_preset=”default” custom_button=”on” button_bg_color=”RGBA(0,0,0,0)” text_orientation=”left” custom_margin=”40px||40px||false|false” custom_padding=”0px||||false|false” sticky_position=”top” sticky_offset_top=”20px” border_color_all=”#4B0084″ disabled=”on” global_module=”4991″ saved_tabs=”all”][et_pb_social_media_follow_network social_network=”instagram” url=”https:\/\/www.instagram.com\/neurocru” _builder_version=”4.9.10″ _module_preset=”default” follow_button=”off” url_new_window=”on”]instagram[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.9.10″ text_font_size=”17px” text_line_height=”1.2em” background_color=”#4B0084″ width=”300%” max_width=”150px” custom_margin=”110px|80px||5px|false|false” custom_padding=”10px|3px|10px|13px|false|false” link_option_url=”https:\/\/cru.mcgill.ca\/fr\/essais\/” border_radii=”on|12px|12px|12px|12px”]<\/p>\n

Pour tous les essais en cours,\u00a0 visitez cru.mcgill.ca\/fr\/essais<\/span><\/a><\/span><\/strong>.<\/a><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

\u00c0 propos L’\u00e9quipe Investigateurs Principaux \u00c9tudes en recrutement Autisme AVC D\u00e9mence \u00c9pilepsie Migraine Neuro-Chirurgie Neuromusculaire Neuro-oncologie Parkinson Scl\u00e9rose en plaques SLA Soins intensifs Patients Professionnels Nouvelles Carri\u00e8res Nous joindre EN R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares 9 janvier 2023par Sophie Lorenzo L\u2019Unit\u00e9 de recherche clinique (URC) […]<\/p>\n","protected":false},"author":12,"featured_media":7700,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"2880","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[253,16],"tags":[],"yoast_head":"\nR\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares - Clinical Research Unit<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares - Clinical Research Unit\" \/>\n<meta property=\"og:description\" content=\"\u00c0 propos L’\u00e9quipe Investigateurs Principaux \u00c9tudes en recrutement Autisme AVC D\u00e9mence \u00c9pilepsie Migraine Neuro-Chirurgie Neuromusculaire Neuro-oncologie Parkinson Scl\u00e9rose en plaques SLA Soins intensifs Patients Professionnels Nouvelles Carri\u00e8res Nous joindre EN R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares 9 janvier 2023par Sophie Lorenzo L\u2019Unit\u00e9 de recherche clinique (URC) […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Research Unit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cru.mcgill\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-09T21:23:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-03T13:11:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cru.mcgill.ca\/wp-content\/uploads\/CRU-web-images.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2050\" \/>\n\t<meta property=\"og:image:height\" content=\"780\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sophie Lorenzo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/cru.mcgill.ca\/#organization\",\"name\":\"Clinical Research Unit\",\"url\":\"https:\/\/cru.mcgill.ca\/\",\"sameAs\":[\"https:\/\/www.facebook.com\/cru.mcgill\/\"],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/cru.mcgill.ca\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cru.mcgill.ca\/wp-content\/uploads\/CRUlogo.png\",\"contentUrl\":\"https:\/\/cru.mcgill.ca\/wp-content\/uploads\/CRUlogo.png\",\"width\":268,\"height\":150,\"caption\":\"Clinical Research Unit\"},\"image\":{\"@id\":\"https:\/\/cru.mcgill.ca\/#\/schema\/logo\/image\/\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cru.mcgill.ca\/#website\",\"url\":\"https:\/\/cru.mcgill.ca\/\",\"name\":\"Clinical Research Unit\",\"description\":\"CRU at the Neuro (Montreal Neurological Institute-Hospital)\",\"publisher\":{\"@id\":\"https:\/\/cru.mcgill.ca\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cru.mcgill.ca\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/\",\"url\":\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/\",\"name\":\"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares - Clinical Research Unit\",\"isPartOf\":{\"@id\":\"https:\/\/cru.mcgill.ca\/#website\"},\"datePublished\":\"2022-11-09T21:23:06+00:00\",\"dateModified\":\"2023-06-03T13:11:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cru.mcgill.ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/\"},\"author\":{\"name\":\"Sophie Lorenzo\",\"@id\":\"https:\/\/cru.mcgill.ca\/#\/schema\/person\/266a30ffc001c61839f97201c1f026a4\"},\"headline\":\"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares\",\"datePublished\":\"2022-11-09T21:23:06+00:00\",\"dateModified\":\"2023-06-03T13:11:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/\"},\"wordCount\":1747,\"publisher\":{\"@id\":\"https:\/\/cru.mcgill.ca\/#organization\"},\"articleSection\":[\"Neuromusculaire\",\"News-fr\"],\"inLanguage\":\"en-CA\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cru.mcgill.ca\/#\/schema\/person\/266a30ffc001c61839f97201c1f026a4\",\"name\":\"Sophie Lorenzo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/cru.mcgill.ca\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ab462456dff4c532792084271212e322?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ab462456dff4c532792084271212e322?s=96&d=mm&r=g\",\"caption\":\"Sophie Lorenzo\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares - Clinical Research Unit","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/","og_locale":"en_US","og_type":"article","og_title":"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares - Clinical Research Unit","og_description":"\u00c0 propos L’\u00e9quipe Investigateurs Principaux \u00c9tudes en recrutement Autisme AVC D\u00e9mence \u00c9pilepsie Migraine Neuro-Chirurgie Neuromusculaire Neuro-oncologie Parkinson Scl\u00e9rose en plaques SLA Soins intensifs Patients Professionnels Nouvelles Carri\u00e8res Nous joindre EN R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares 9 janvier 2023par Sophie Lorenzo L\u2019Unit\u00e9 de recherche clinique (URC) […]","og_url":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/","og_site_name":"Clinical Research Unit","article_publisher":"https:\/\/www.facebook.com\/cru.mcgill\/","article_published_time":"2022-11-09T21:23:06+00:00","article_modified_time":"2023-06-03T13:11:08+00:00","og_image":[{"width":2050,"height":780,"url":"https:\/\/cru.mcgill.ca\/wp-content\/uploads\/CRU-web-images.jpg","type":"image\/jpeg"}],"author":"Sophie Lorenzo","twitter_card":"summary_large_image","twitter_misc":{"Written by":false,"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/cru.mcgill.ca\/#organization","name":"Clinical Research Unit","url":"https:\/\/cru.mcgill.ca\/","sameAs":["https:\/\/www.facebook.com\/cru.mcgill\/"],"logo":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/cru.mcgill.ca\/#\/schema\/logo\/image\/","url":"https:\/\/cru.mcgill.ca\/wp-content\/uploads\/CRUlogo.png","contentUrl":"https:\/\/cru.mcgill.ca\/wp-content\/uploads\/CRUlogo.png","width":268,"height":150,"caption":"Clinical Research Unit"},"image":{"@id":"https:\/\/cru.mcgill.ca\/#\/schema\/logo\/image\/"}},{"@type":"WebSite","@id":"https:\/\/cru.mcgill.ca\/#website","url":"https:\/\/cru.mcgill.ca\/","name":"Clinical Research Unit","description":"CRU at the Neuro (Montreal Neurological Institute-Hospital)","publisher":{"@id":"https:\/\/cru.mcgill.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cru.mcgill.ca\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-CA"},{"@type":"WebPage","@id":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/","url":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/","name":"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares - Clinical Research Unit","isPartOf":{"@id":"https:\/\/cru.mcgill.ca\/#website"},"datePublished":"2022-11-09T21:23:06+00:00","dateModified":"2023-06-03T13:11:08+00:00","breadcrumb":{"@id":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cru.mcgill.ca\/"},{"@type":"ListItem","position":2,"name":"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares"}]},{"@type":"Article","@id":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/#article","isPartOf":{"@id":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/"},"author":{"name":"Sophie Lorenzo","@id":"https:\/\/cru.mcgill.ca\/#\/schema\/person\/266a30ffc001c61839f97201c1f026a4"},"headline":"R\u00e9trospective 2022 : collaborations en science ouverte et de grandes victoires pour les maladies rares","datePublished":"2022-11-09T21:23:06+00:00","dateModified":"2023-06-03T13:11:08+00:00","mainEntityOfPage":{"@id":"https:\/\/cru.mcgill.ca\/fr\/2022-retrospective\/"},"wordCount":1747,"publisher":{"@id":"https:\/\/cru.mcgill.ca\/#organization"},"articleSection":["Neuromusculaire","News-fr"],"inLanguage":"en-CA"},{"@type":"Person","@id":"https:\/\/cru.mcgill.ca\/#\/schema\/person\/266a30ffc001c61839f97201c1f026a4","name":"Sophie Lorenzo","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/cru.mcgill.ca\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ab462456dff4c532792084271212e322?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ab462456dff4c532792084271212e322?s=96&d=mm&r=g","caption":"Sophie Lorenzo"}}]}},"_links":{"self":[{"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/posts\/7708"}],"collection":[{"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/comments?post=7708"}],"version-history":[{"count":11,"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/posts\/7708\/revisions"}],"predecessor-version":[{"id":7743,"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/posts\/7708\/revisions\/7743"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/media\/7700"}],"wp:attachment":[{"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/media?parent=7708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/categories?post=7708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cru.mcgill.ca\/wp-json\/wp\/v2\/tags?post=7708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}